Latest Breaking News On - மஜேன் தர்வாசா - Page 1 : comparemela.com

Published: Apr 29, 2021     MORRISTOWN, N.J. (BUSINESS WIRE) Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region. In the United States, Orbactiv ® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections due to designated susceptible Gram-positive pathogens and Vabomere ® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Gram-negative pathogens.

United statesUnited arab emiratesUnited kingdomChristine ann millerMazen darwazahPharmaceuticals inc melintaHikma pharmaceuticalsMelinta therapeuticsRibx pharmaceuticalsMiddle eastNorth africaExecutive vice chairmanChief executive officerஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது அரபு அமீரகங்கள்ஒன்றுபட்டது கிஂக்டம்